Persistent treatment failure in lung cancer may have found an unexpected culprit: growth hormone signaling that helps tumors evade destruction. This discovery opens a potential pathway to overcome one of oncology's most stubborn challenges using existing FDA-approved compounds.
Non-small cell lung cancer cells exploit growth hormone receptor (GHR) signaling to survive chemotherapy through multiple resistance mechanisms. Elevated GHR expression correlates with shortened patient survival and activates drug-efflux pumps that literally pump chemotherapy out of cancer cells before it can work. The hormone also triggers epithelial-to-mesenchymal transition, transforming cells into more mobile, invasive forms while simultaneously blocking programmed cell death pathways.
The therapeutic implications appear promising because pegvisomant, an existing growth hormone receptor antagonist used for acromegaly, successfully reversed these resistance mechanisms in laboratory studies. When combined with standard chemotherapy, pegvisomant restored drug sensitivity by dismantling the cellular machinery that cancer cells use for survival and metastasis.
This represents a compelling example of drug repurposing, where medications developed for entirely different conditions find new applications in cancer treatment. The growth hormone-cancer connection has emerged across multiple tumor types, suggesting broader implications beyond lung cancer. However, translating these laboratory findings into clinical practice requires careful consideration of growth hormone's essential roles in healthy tissue repair and metabolism. The challenge lies in selectively targeting tumor-associated GHR signaling without compromising normal physiological functions, particularly in patients already weakened by cancer and chemotherapy.